Volume 69, Issue 5, Pages (May 2016)

Slides:



Advertisements
Similar presentations
European Urology Focus
Advertisements

The PSA Era is not Over for Prostate Cancer
Volume 54, Issue 2, Pages (August 2008)
Volume 69, Issue 3, Pages (March 2016)
Volume 50, Issue 1, Pages (July 2006)
Volume 60, Issue 2, Pages (August 2011)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Testosterone Therapy in Men With Prostate Cancer
David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono 
Volume 69, Issue 5, Pages (May 2016)
Volume 68, Issue 6, Pages e129-e131 (December 2015)
Volume 53, Issue 4, Pages (April 2008)
Volume 68, Issue 4, Pages (October 2015)
Volume 66, Issue 5, Pages (November 2014)
Volume 61, Issue 5, Pages (May 2012)
Volume 74, Issue 2, Pages (August 2018)
Volume 69, Issue 5, Pages (May 2016)
Managing Nonmetastatic Castration-resistant Prostate Cancer
Volume 68, Issue 1, Pages (July 2015)
Volume 52, Issue 3, Pages (September 2007)
Prostate Cancer Epidemic in Sight?
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology  Philipp.
Volume 71, Issue 2, Pages (February 2017)
Volume 68, Issue 4, Pages (October 2015)
Volume 63, Issue 2, Pages (February 2013)
Volume 65, Issue 5, Pages (May 2014)
Volume 74, Issue 1, Pages (July 2018)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 71, Issue 1, Pages 1-3 (January 2017)
Volume 70, Issue 4, Pages (October 2016)
Volume 69, Issue 3, Pages (March 2016)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Detection: A View of the Future
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 56, Issue 2, Pages (August 2009)
Volume 66, Issue 3, Pages (September 2014)
Volume 66, Issue 5, Pages (November 2014)
Volume 70, Issue 5, Pages (November 2016)
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 73, Issue 5, Pages (May 2018)
Volume 53, Issue 4, Pages (April 2008)
Volume 72, Issue 1, Pages (July 2017)
Volume 66, Issue 2, Pages (August 2014)
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 74, Issue 2, Pages (August 2018)
Volume 68, Issue 4, Pages (October 2015)
Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Volume 71, Issue 2, Pages (February 2017)
Volume 50, Issue 5, Pages (November 2006)
Volume 55, Issue 6, Pages (June 2009)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Volume 74, Issue 3, Pages (September 2018)
Volume 70, Issue 1, Pages (July 2016)
Volume 71, Issue 4, Pages (April 2017)
European Urology is “Your” Journal
Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg 
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Volume 69, Issue 5, Pages (May 2016)
European Urology Oncology
Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson 
Volume 53, Issue 2, Pages (February 2008)
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Volume 69, Issue 4, Pages (April 2016)
Presentation transcript:

Volume 69, Issue 5, Pages 834-840 (May 2016) Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study  Christophe Massard, Heidi M. Penttinen, Egils Vjaters, Petri Bono, Vilnis Lietuvietis, Teuvo L. Tammela, Annamari Vuorela, Pirjo Nykänen, Pasi Pohjanjousi, Amir Snapir, Karim Fizazi  European Urology  Volume 69, Issue 5, Pages 834-840 (May 2016) DOI: 10.1016/j.eururo.2015.09.046 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 Study overview: (A) trial design; (B) schedule of events. b.i.d.=twice daily; EOS=end of study; PK=pharmacokinetic; TabA=tablet A; TabB=tablet B. European Urology 2016 69, 834-840DOI: (10.1016/j.eururo.2015.09.046) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 2 Plasma concentration-time curve for ODM-201 following single-dose administration of capsule, tablet A, and tablet B. European Urology 2016 69, 834-840DOI: (10.1016/j.eururo.2015.09.046) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 3 (A) Percentage change in prostate-specific antigen (PSA) at 12 wk compared with baseline, (B) time to PSA progression by Prostate Cancer Working Group 2 criterion, and (C) time to radiographic progression. PSA=prostate-specific antigen. European Urology 2016 69, 834-840DOI: (10.1016/j.eururo.2015.09.046) Copyright © 2015 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.